Dr. Ramez Eskander, MD, Chief Scientific Advisor and Dr. Anne Mette Buhl, PhD, Director of Science and Clinical Trials welcome special guest, Dr. Alberto Mendivil, MD, Co-Director, Gynecologic Oncology, Hoag Memorial Hospital Presbyterian.
They cover: * Overview of current platinum-based therapies * NCCN Guidelines for PPROC patients * Innovative approaches being explored
Dr. Mendivil is board certified in Obstetrics and Gynecology as well as Gynecologic Oncology. He serves as the Principal Investigator for the OnPrime Phase 3 Registration Trial, which is currently enrolling. He has extensive training in all aspects of gynecologic surgery including advanced laparoscopy and robotics and leads the gynecologic cancer clinical trials at Hoag Family Cancer Institute.
The information discussed in the presentation is also available on our website (please copy/paste URLs into your browser):
Understanding the terminology: platinum sensitive/resistant/refractory
www.clearityfo...
Approved standard of care treatment options for platinum resistant or refractory recurrence
www.clearityfo...
Select tab "Treatments for Platinum Resistant and Refractory", then tab "Standard of Care Treatments"
Active Phase III clinical trials for platinum resistant ovarian cancer
www.clearityfo...
Select tab "Treatments for Platinum Resistant and Refractory", then tab "Clinical trials in late stage development"
NCCN guidelines version 2.2024 (May 2024) - Recurrence Therapy for Platinum Resistant Disease
www.clearityfo...
To have a one-on-one consultation with a Clearity team member, please visit our Treatment Decision Support page, complete the registration form and provide the records requested.
www.clearityfo...
Special thanks to our generous sponsor, Genelux, for making this webinar happen. Learn more about the OnPrime trial using this link.
go.clearity.or...
Негізгі бет Platinum Resistant Refractory Ovarian Cancer - Despite limited options, there is reason for hope
Пікірлер